BREAKING — Telepatia AI raises $42M total to build an "AI Doctor" for Latin America a16z leads $33M Series A 14M+ patients across 5 countries ~2 hours saved per physician, per day Integrated with 50+ hospital systems Goal: assist half of LatAm's 1.9M doctors by 2027
Company Dossier · HealthTech

Telepatia AI

The AI Doctor that listens to the visit, writes the chart, and quietly hands physicians back the two hours they lost to the keyboard.

$42MTotal Raised
14M+Patients
5Countries
50+Systems
Telepatia AI logo
FIG.1 — The wordmark. Named for a father who never forgot a name.
Share the file:
The Scene

Somewhere in Brazil, a doctor isn't typing.

It is mid-morning at Hospital Mater Dei. A physician is talking to a patient - actually talking, eyes up, hands still. There is no laptop screen swallowing the conversation, no half-heard symptom lost to a keyboard. In the background, Telepatia is listening. By the time the patient stands to leave, the note is already written, structured, and waiting for a signature.

This is the small, unglamorous miracle Telepatia AI is selling: not a robot that replaces the doctor, but a scribe that removes the paperwork standing between the doctor and the person in front of them. In a region where physicians can spend up to 70% of their day on administrative work, giving back two hours is not a feature. It is oxygen.

The company calls its product an "AI Doctor." Founder Nicolas Abad prefers a humbler phrase - a second brain for the physician. It transcribes the visit, structures the record, reviews it for errors, and offers evidence-based suggestions from the medical literature while the doctor works. The doctor stays in charge. The typing goes away.

"A second brain for the doctor." — Nicolas Abad, Co-founder & CEO
The Two-Hour Tax
Time on admin (typical LatAm clinic)40–70%
Hours recovered per physician / day~1.7–2h
Protocol adherence improvement+15%

Figures reported by the company; treat as approximate directional claims.

The Name

Telepathy, in the medical sense

The company is named after Abad's father, nicknamed "Telepatia" for a memory so sharp it seemed like mind-reading - he never forgot a name, a face, a detail. When his father died in 2022 from what has been described as a preventable drug interaction, the loss reframed the problem. Medicine does not usually fail for lack of knowledge. It fails when the right detail arrives at the wrong moment, or not at all.

So the pitch is personal. Build software that never forgets the detail - the interaction, the allergy, the last lab value - and put it in the room while the decision is being made. The name is a promise dressed as a nickname.

The founders are an unlikely, complementary pair from Medellin. Nicolas Abad is an economist from EAFIT with a Stanford MBA, where the company was incubated. Tomas Giraldo is a physician trained at CES who paused his medical specialization to build it - the clinical conscience of a technology company.

Between them: one who understands the market and the machine, and one who has actually filled out the forms. It is a founding team that has felt the problem from both ends of the stethoscope.

FIG.2 — Two founders, one economist and one doctor. Business plan meets bedside.

The Toolkit

Four tools, one shift off the doctor's shoulders

Documentation

AI Writer

Real-time transcription of the visit that structures the encounter into a clean clinical note and electronic health record - written as the conversation happens.

Decision Support

AI Advisor

A clinical copilot that reviews the record, flags potential errors, and surfaces evidence-based suggestions drawn from medical literature and guidelines.

Interoperability

AI Integrator

Connects to 50+ healthcare systems - Epic, TASY, MV, iClinic - so documentation flows into the hospital software already in place.

Analytics

AI Business Intelligence

Dashboards for clinical metrics, protocol adherence, and performance across a whole institution, not just a single visit.

FIG.3 — The stack: listen, structure, advise, connect, measure.

$9MSeed · Oct 2025
$33MSeries A · a16z-led
$42MTotal Raised
25+Health Institutions
The Money

A rare thing: an a16z-led round for public hospitals

Telepatia's seed round, reported as one of the largest in the region at $9M, was led by A-Star with Canary, Abstract, Picus, SV Angel, and Nido along for the ride. Then Andreessen Horowitz led a $33M Series A, bringing the total to $42M and pointing the company squarely at Brazil.

The early cap table reads like a Latin American tech hall of fame: the CTO of Palantir, the founder of Rappi, the founder of Nubank. When the people who built the region's biggest software companies write personal checks, it tends to mean something.

a16zA-StarCanary AbstractPicusSV AngelNido
OCT 2025

Seed — $9M

Led by A-Star; one of the largest seed rounds reported in the region.

2025

Series A — $33M

Led by Andreessen Horowitz to fund expansion, notably across Brazil.

TODAY

$42M total · 14M+ patients

Deployed in 25+ institutions across Brazil, Colombia, Mexico, Chile, and Argentina.

The Founders

Business plan, meet bedside

Co-founder & CEO

Nicolas Abad

Economist from EAFIT with a Stanford MBA, where Telepatia was incubated. Named the company after his late father and frames the product as "a second brain for the doctor."

Co-founder & Director of Medical Affairs

Tomas Giraldo Hinestroza

Physician trained at CES in Medellin who paused his medical specialization to build the company - the clinical voice keeping the technology honest to real practice.

The Users

Who's actually keeping it open eight hours a day

Adoption depth is the real scoreboard. At one flagship hospital, physicians reportedly keep Telepatia open around eight hours a day - roughly a full shift. That is not a demo that impresses; it is a habit that sticks.

Hospital Mater Dei

Flagship Brazilian deployment - ~1.7 hours recovered per physician, per day.

Kora Saude & Hapvida

Major Brazilian hospital and health networks running clinical documentation on Telepatia.

Public Networks

Public health systems in Bogota, Medellin, and Barranquilla.

Colombian Institutions

Fundacion Santa Fe de Bogota, Colsubsidio, Comfama, and more.

FIG.4 — From private hospitals to public networks; from Sao Paulo to Barranquilla.

The Stakes

You can't hire your way out of a doctor shortage

Brazil and Colombia have roughly one-third fewer doctors per capita than the OECD average. You cannot train that gap away quickly. Telepatia's wager is that you can, at least partly, software your way toward it - by making every existing physician meaningfully more productive.

The stated goal is bold and specific: assist half of Latin America's 1.9 million doctors by the end of 2027. After that, the map points to India, Africa, and Southeast Asia - other markets where doctors are scarce and paperwork is not.

Assist half of Latin America's 1.9 million doctors by the end of 2027. — Telepatia's stated mission
The Field

Ambient AI is crowded. The region isn't.

The ambient-scribe category has real players - Abridge, Nabla, Suki, Nuance's DAX Copilot, Corti. Most are built for the United States and Europe. Telepatia's edge is narrower and deeper: Latin American languages, local hospital systems like TASY and MV, and compliance with both LGPD and HIPAA. It is easier to win a room that others aren't fighting for.

vs Abridge vs Nabla vs Suki vs Nuance DAX vs Corti
Back to the Scene

The patient stands to leave. The note is done.

Return to that exam room in Brazil. The visit is over. The physician did not spend the encounter narrating into a screen, and will not spend the evening catching up on charts. The note is written, structured, and checked. The next patient is already waiting - and will get eye contact instead of the top of a doctor's head.

That is the whole thesis, small enough to fit in a sentence: put the paperwork on the machine so the medicine can go back to the person. A company named after a man who never forgot a detail is betting the future of Latin American care on software that doesn't either. It started with a loss. It is trying to prevent a few million more.